Savara Inc. News

Latest updates and market news for SVRA

4 news

Mar 3 - Mar 9, 2026

Page 1

MT Newswires

3 days ago

Savara Says FDA Letter Indicates No Advisory Committee Meeting Planned for Molbreevi Application

Savara Provides Regulatory Update on the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Business Wire

3 days ago

Savara Provides Regulatory Update on the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Savara (SVRA) Is Down 8.0% After FDA Grants Priority Review To MOLBREEVI - What's Changed

Simply Wall St.

3 days ago

Savara (SVRA) Is Down 8.0% After FDA Grants Priority Review To MOLBREEVI - What's Changed

📊

AI Sentiment

Positive

6/10

Savara Announces Participation in 2026 Citizens Life Sciences Conference

Business Wire

5 days ago

Savara Announces Participation in 2026 Citizens Life Sciences Conference

Share this news page

Share on Social Networks: